In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy ...

The deal with China’s Chimagen Biosciences is the latest example of pharma interest in exploring the potential of “T cell engagers” in autoimmune disease.

GlaxoSmithKline (GSK) has agreed to acquire Chimagen Biosciences’ CMG1A46, a clinical-stage therapy designed to target B cell ...

UK pharma major GSK is to buy CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from privately-held ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to ...

GSK plc and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The candidate in question is CMG1A46, a dual CD19- and CD20-targeted T cell engager that Chimagen Biosciences is currently evaluating in phase 1 trials for leukemia and lymphoma. However, GSK has ...

(Alliance News) - GSK PLC on Tuesday said that it has signed a deal to buy CMG1A46 from Chimagen Biosciences for USD300 million upfront. The London-based pharmaceutical and biotechnology firm plans to ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...

LONDON, UK I9, 2024 I GSK plc (LSE/NYSE: GSK) and Chimagen Biosciences (Chimagen), a privately held biotechnology company, today announced an ...